Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol addiction, metabolic liver disease (particularly nonalcoholic fatty liver disease) and exposure to dietary toxins such as aflatoxins and aristolochic acid. All these risk factors are potentially preventable, highlighting the considerable potential of risk prevention for decreasing the global burden of HCC. HCC surveillance and early detection increase the chance of potentially curative treatment; however, HCC surveillance is substantially underutilized, even in countries with sufficient medical resources. Early-stage HCC can be treated curatively by local ablation, surgical resection or liver transplantation. Treatment selection depends on tumour characteristics, the severity of underlying liver dysfunction, age, other medical comorbidities, and available medical resources and local expertise. Catheter-based locoregional treatment is used in patients with intermediate-stage cancer. Kinase and immune checkpoint inhibitors have been shown to be effective treatment options in patients with advanced-stage HCC. Together, rational deployment of prevention, attainment of global goals for viral hepatitis eradication, and improvements in HCC surveillance and therapy hold promise for achieving a substantial reduction in the worldwide HCC burden within the next few decades.
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide; >80% of HCC cases occur in low-resource and middle-resource countries, particularly in Eastern Asia and sub-Saharan Africa, where medical and social care resources are often constrained.
Prevention and treatment of viral hepatitis and mitigation of exposure to aflatoxin and aristolochic acid, the main risk factors in high-incidence regions, are critical for decreasing the global burden of HCC.
HCC surveillance enables early detection and increases the chance of potentially curative treatment; therefore, broad implementation of HCC surveillance in high-risk patients is essential to reduce the high mortality from HCC.
Early-stage HCC is amenable to potentially curative treatment, which includes local ablation, surgical resection and liver transplantation.
Catheter-based locoregional treatment is indicated in patients with intermediate-stage disease; kinase and immune checkpoint inhibitors have been shown to be effective treatment options in patients with advanced-stage HCC.
Global reduction of HCC burden can be achieved by universal HBV vaccination, control of chronic viral hepatitis, avoiding environmental and lifestyle risk factors, and improving early detection and management.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis
Stem Cell Research & Therapy Open Access 04 October 2022
Establishment and validation of a novel prognostic model for non-virus-related hepatocellular carcinoma
Cancer Cell International Open Access 02 October 2022
Journal of Nanobiotechnology Open Access 29 September 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Global Burden of Disease Cancer, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 3, 524–548 (2017).
El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557–2576 (2007).
El-Serag, H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264–1273 e1261 (2012).
Tang, A., Hallouch, O., Chernyak, V., Kamaya, A. & Sirlin, C. B. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom. Radiol. (NY) 43, 13–25 (2018).
Altekruse, S. F., McGlynn, K. A. & Reichman, M. E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27, 1485–1491 (2009).
Hajarizadeh, B., Grebely, J. & Dore, G. J. Epidemiology and natural history of HCV infection. Nat. Rev. Gastroenterol. Hepatol. 10, 553–562 (2013).
Park, J. W. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the bridge study. Liver Int. 35, 2155–2166 (2015).
Yang, J. D. et al. Hepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic hepatitis B. Am. J. Gastroenterol. 110, 1629–1631 (2015).
Yang, J. D., Altekruse, S. F., Nguyen, M. H., Gores, G. J. & Roberts, L. R. Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer 123, 81–89 (2017).
Yang, J. D. et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol. Hepatol. 2, 103–111 (2017).
Kudo, M. Management of hepatocellular carcinoma in Japan as a world-leading model. Liver Cancer 7, 134–147 (2018).
Yang, J. D. & Roberts, L. R. Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 7, 448–458 (2010).
World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. WHO https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ (2016).
Heffernan, A., Cooke, G. S., Nayagam, S., Thursz, M. & Hallett, T. B. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet 393, 1319–1329 (2019).
Yang, J. D. et al. Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis c cirrhosis. Am. J. Gastroenterol. 111, 1573–1580 (2016).
Chayanupatkul, M. et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J. Hepatol. 66, 355–362 (2017).
Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577–1586 (2016).
Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
Younossi, Z. M. et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62, 1723–1730 (2015).
Yang, J. D. et al. Recent trends in the epidemiology of hepatocellular carcinoma in Olmsted county, Minnesota: a US population-based study. J. Clin. Gastroenterol. 51, 742–748 (2017).
Welzel, T. M. et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 108, 1314–1321 (2013).
Mittal, S. et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 14, 124–131 e121 (2016).
El-Serag, H. B., Hampel, H. & Javadi, F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 4, 369–380 (2006).
Huang, S. F. et al. Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatol. Commun. 2, 747–759 (2018).
Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).
Hirosumi, J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333–336 (2002).
Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E. & Wagner, E. F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 118, 3943–3953 (2008).
Norat, T., Aune, D., Navarro, D. & Abar, L. Diet, nutrition, physical activity and liver cancer. World Cancer Research Fund International. https://www.wcrf.org/sites/default/files/Liver-Cancer-2015-Report.pdf (2015).
West, J., Card, T. R., Aithal, G. P. & Fleming, K. M. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment. Pharmacol. Ther. 45, 983–990 (2017).
Jepsen, P., Ott, P., Andersen, P. K., Sorensen, H. T. & Vilstrup, H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann. Intern. Med. 156, 841–847, W295 (2012).
Mancebo, A. et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin. Gastroenterol. Hepatol. 11, 95–101 (2013).
Wild, C. P., Miller, J. D. & Groopman, J. D. Mycotoxin Control in Low- and Middle-Income Countries Vol. 9 (IARC, 2015).
Gouas, D., Shi, H. & Hainaut, P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett. 286, 29–37 (2009).
Weng, M. W. et al. AFB1 hepatocarcinogenesis is via lipid peroxidation that inhibits DNA repair, sensitizes mutation susceptibility and induces aldehyde-DNA adducts at p53 mutational hotspot codon 249. Oncotarget 8, 18213–18226 (2017).
Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 15, 585–598 (2014).
Shen, H. M. & Ong, C. N. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat. Res. 366, 23–44 (1996).
Ross, R. K. et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339, 943–946 (1992).
Kew, M. C. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 23, 405–409 (2003).
Arlt, V. M., Stiborova, M. & Schmeiser, H. H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17, 265–277 (2002).
Rosenquist, T. A. & Grollman, A. P. Mutational signature of aristolochic acid: clue to the recognition of a global disease. DNA Repair (Amst.) 44, 205–211 (2016).
Ng, A. W. T. et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci. Transl Med. 9, eaan6446 (2017).
Hsieh, S. C., Lin, I. H., Tseng, W. L., Lee, C. H. & Wang, J. D. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin. Med. 3, 13 (2008).
Chen, C. J. et al. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. In. J. Cancer, 143, 1578–1587 (2018).
Bravi, F., Tavani, A., Bosetti, C., Boffetta, P. & La Vecchia, C. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur. J. Cancer Prev. 26, 368–377 (2017).
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144, 323–332 (2013).
Zhou, Y. Y. et al. Systematic review with network meta-analysis: antidiabetic medication and risk of hepatocellular carcinoma. Sci. Rep. 6, 33743 (2016).
Sahasrabuddhe, V. V. et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J. Natl Cancer Inst. 104, 1808–1814 (2012).
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 69, 182–236 (2018).
Kim, W. R. et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 121, 3631–3638 (2015).
van der Meer, A. J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308, 2584–2593 (2012).
El-Serag, H. B., Kanwal, F., Richardson, P. & Kramer, J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology 64, 130–137 (2016).
Kanwal, F. et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153, 996–1005 e1001 (2017).
Reig, M. et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 65, 719–726 (2016).
Conti, F. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J. Hepatol. 65, 727–733 (2016).
Yang, J. D. et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J. Hepatol. 65, 859–860 (2016).
Ravi, S. et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis c related cirrhosis. Gastroenterology 152, 911–912 (2017).
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J. Hepatol. 65, 734–740 (2016).
Petta, S. et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment. Pharmacol. Ther. 45, 160–168 (2017).
Singal, A. G. et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology 156, 1683–1692 (2019).
Nahon, P. et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology 155, 1436–1450 e1436 (2018).
The Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327–1341 e1323 (2017).
Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505–511 (2015).
Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385–7392 (2009).
Amaddeo, G. et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut 64, 820–829 (2015).
Boyault, S. et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42–52 (2007).
Calderaro, J. et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J. Hepatol. 67, 727–738 (2017).
Harding, J. J. et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 25, 2116–2126 (2019).
Chang, M. H. et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 151, 472–480 (2016).
World Health Organization. WHO–UNICEF estimates of HepB3 coverage. WHO. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragehepb3.html (2019).
Jourdain, G. et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N. Engl. J. Med. 378, 911–923 (2018).
Eke, A. C., Eleje, G. U., Eke, U. A., Xia, Y. & Liu, J. Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database Syst. Rev. 2, CD008545 (2017).
Smith, B. D. et al. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the centers for disease control and prevention. Ann. Intern. Med. 157, 817–822 (2012).
Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S. & Lok, A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol. 53, 348–356 (2010).
Thoms, D. L. Global elimination of chronic hepatitis. N. Engl. J. Med. 380, 2041–2050 (2019).
Patel, N. S. et al. Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 15, 463–464 (2017).
Petrick, J. L. et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project. Br. J. Cancer 118, 1005–1012 (2018).
Liu, Y., Chang, C. C., Marsh, G. M. & Wu, F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur. J. Cancer 48, 2125–2136 (2012).
Turner, P. C. et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in West Africa: a community-based intervention study. Lancet 365, 1950–1956 (2005).
Chen, J. G. et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev. Res. 6, 1038–1045 (2013).
Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 68, 723–750 (2018).
Papatheodoridis, G. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in caucasians with chronic hepatitis B on 5-year antiviral therapy. J. Hepatol. 64, 800–806 (2016).
Singal, A. G., Pillai, A. & Tiro, J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLOS Med. 11, e1001624 (2014).
National Cancer Institute (ed.) PDQ Cancer Information Summaries, 2019. https://www.ncbi.nlm.nih.gov/books/NBK65785/ (NCBI, 2019).
Poustchi, H. et al. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology 54, 1998–2004 (2011).
Tan, C. H., Low, S. C. & Thng, C. H. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int. J. Hepatol. 2011, 519783 (2011).
Santi, V. et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J. Hepatol. 53, 291–297 (2010).
Trinchet, J. C. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 54, 1987–1997 (2011).
Chang, T. S. et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am. J. Gastroenterol. 110, 836–845 (2015).
McMahon, B. J. et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 32, 842–846 (2000).
Yang, J. D. et al. Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase. Cancer Epidemiol. Biomarkers Prev. 26, 1085–1092 (2017).
El-Serag, H. B., Kanwal, F., Davila, J. A., Kramer, J. & Richardson, P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 146, 1249–1255 (2014).
Tayob, N., Lok, A. S., Do, K. A. & Feng, Z. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clin. Gastroenterol. Hepatol. 14, 469–475 (2016).
Marrero, J. A. et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137, 110–118 (2009).
Lok, A. S. et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138, 493–502 (2010).
Berhane, S. et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin. Gastroenterol. Hepatol. 14, 875–886 (2016).
Johnson, P. J. et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol. Biomarkers Prev. 23, 144–153 (2014).
Yang, J. D. et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol. Biomarkers Prev. 28, 531–538 (2019).
Lin, X. J. et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 16, 804–815 (2015).
Zhao, Y. et al. Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma. Clin. Epigenet. 6, 30 (2014).
Liao, W. et al. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis. Medicine 94, e722 (2015).
Shang, S. et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55, 483–490 (2012).
Kisiel, J. B. et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation. Hepatology 69, 1180–1192 (2019).
Atiq, O. et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 65, 1196–1205 (2017).
Rich, N. E., Parikh, N. D. & Singal, A. G. Overdiagnosis: an understudied issue in hepatocellular carcinoma surveillance. Semin. Liver Dis. 37, 296–304 (2017).
Mitchell, D. G., Bruix, J., Sherman, M. & Sirlin, C. B. LI-RADS (liver imaging reporting and data system): summary, discussion, and consensus of the LI-RADS management working group and future directions. Hepatology 61, 1056–1065 (2015).
Tang, A. et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 286, 29–48 (2018).
Liu, P. H. et al. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J. Hepatol. 64, 601–608 (2016).
Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329–338 (1999).
Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391, 1301–1314 (2018).
Giannini, E. G. et al. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma. Am. J. Gastroenterol. 111, 70–77 (2016).
Kudo, M. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40, 1396–1405 (2004).
Hiraoka, A. et al. Proposed new sub-grouping for intermediate-stage hepatocellular carcinoma using albumin-bilirubin grade. Oncology 91, 153–161 (2016).
Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J. Clin. Oncol. 33, 550–558 (2015).
Yau, T. et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146, 1691–1700 (2014).
Sohn, J. H. et al. Validation of the Hong Kong liver cancer staging system in determining prognosis of the North American patients following intra-arterial therapy. Clin. Gastroenterol. Hepatol. 15, 746–755 (2017).
Wu, L., Bartlett, A., Plank, L. & McCall, J. Validation of the Hong Kong liver cancer staging system in hepatocellular carcinoma patients treated with curative intent. J. Hepatol. 64, 978–979 (2016).
Yang, J. D. et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology 56, 614–621 (2012).
Farinati, F. et al. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. PLOS Med. 13, e1002006 (2016).
Toyoda, H. et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin. Gastroenterol. Hepatol. 4, 1528–1536 (2006).
Serper, M. et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology 152, 1954–1964 (2017).
Berzigotti, A., Reig, M., Abraldes, J. G., Bosch, J. & Bruix, J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 61, 526–536 (2015).
Boleslawski, E. et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br. J. Surg. 99, 855–863 (2012).
Teh, S. H. et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J. Gastrointest. Surg. 9, 1207–1215 (2005).
Roayaie, S. et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62, 440–451 (2015).
Kim, H. et al. Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. Br. J. Surg. 104, 1045–1052 (2017).
Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M. & Roayaie, S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann. Surg. 261, 947–955 (2015).
Hoshida, Y. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995–2004 (2008).
Ferrer-Fabrega, J. et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 63, 839–849 (2016).
Hammad, A. Y. et al. Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. Ann. Palliat. Med. 6, 26–35 (2017).
Hawkins, M. A. & Dawson, L. A. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106, 1653–1663 (2006).
Hayashi, S., Tanaka, H. & Hoshi, H. Palliative external-beam radiotherapy for bone metastases from hepatocellular carcinoma. World J. Hepatol. 6, 923–929 (2014).
Yang, J. D. et al. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States. Clin. Gastroenterol. Hepatol. 15, 767–775 (2017).
Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334, 693–699 (1996).
Yao, F. Y. et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 11, 1505–1514 (2005).
Mazzaferro, V. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10, 35–43 (2009).
Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33, 1394–1403 (2001).
Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 8, 765–774 (2002).
Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am. J. Transplant. 7, 2587–2596 (2007).
Yao, F. Y. et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48, 819–827 (2008).
Mehta, N. et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: a multicenter study. Clin. Gastroenterol. Hepatol. 16, 955–964 (2018).
Shiina, S. et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can. J. Gastroenterol. Hepatol. 2018, 4756147 (2018).
Yu, J. et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut 66, 1172–1173 (2017).
Liu, W. et al. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Aliment. Pharmacol. Ther. 48, 671–681 (2018).
Kang, T. W., Lim, H. K. & Cha, D. I. Percutaneous ablation for perivascular hepatocellular carcinoma: refining the current status based on emerging evidence and future perspectives. World. J. Gastroenterol. 24, 5331–5337 (2018).
Vietti Violi, N. et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 3, 317–325 (2018).
Kim, G. M. et al. Cryoablation of hepatocellular carcinoma with high-risk for percutaneous ablation: safety and efficacy. Cardiovasc. Intervent. Radiol. 39, 1447–1454 (2016).
Littrup, P. J. et al. Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series. Abdom. Radiol. 41, 767–780 (2016).
Xu, Y. et al. Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes. Eur. Radiol. 27, 3877–3887 (2017).
Lee, M. W. et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis. Hepatology 65, 1979–1990 (2017).
Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358–380 (2018).
Huang, J. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann. Surg. 252, 903–912 (2010).
Feng, K. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J. Hepatol. 57, 794–802 (2012).
Chen, M. S. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg. 243, 321–328 (2006).
Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S. & Geschwind, J. F. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 64, 106–116 (2016).
Lo, C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164–1171 (2002).
Llovet, J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359, 1734–1739 (2002).
Brown, K. T. et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J. Clin. Oncol. 34, 2046–2053 (2016).
Malagari, K. et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc. Intervent. Radiol. 35, 1119–1128 (2012).
Kulik, L. M. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47, 71–81 (2008).
Sangro, B. et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54, 868–878 (2011).
Salem, R. et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140, 497–507 e492 (2011).
Mazzaferro, V. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57, 1826–1837 (2013).
Salem, R. et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151, 1155–1163 e1152 (2016).
Lobo, L. et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc. Intervent. Radiol. 39, 1580–1588 (2016).
Carr, B. I., Kondragunta, V., Buch, S. C. & Branch, R. A. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116, 1305–1314 (2010).
Chow, P. K. H. et al. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J. Clin. Oncol. 36, 1913–1921 (2018).
Vilgrain, V. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 18, 1624–1636 (2017).
Bush, D. A. et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 95, 477–482 (2016).
Fukuda, K. et al. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 108, 497–503 (2017).
Hong, T. S. et al. Multi-institutional phase ii study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Clin. Oncol. 34, 460–468 (2016).
Igaki, H. et al. A systematic review of publications on charged particle therapy for hepatocellular carcinoma. Int. J. Clin. Oncol. 23, 423–433 (2018).
Sapir, E. et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 100, 122–130 (2018).
Sapisochin, G. et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J. Hepatol. 67, 92–99 (2017).
Teraoka, Y. et al. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma. Hepatol. Res. 48, 193–204 (2018).
Zeng, Z. C. et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific primary liver cancer expert meeting. Liver Cancer 6, 264–274 (2017).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).
Bruix, J. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16, 1344–1354 (2015).
Lencioni, R. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J. Hepatol. 64, 1090–1098 (2016).
Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).
Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).
Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54–63 (2018).
Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282–296 (2019).
Spratlin, J. L. et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28, 780–787 (2010).
El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02576509 (2019).
Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19, 940–952 (2018).
Hainaut, P. & Boyle, P. Curbing the liver cancer epidemic in Africa. Lancet 371, 367–368 (2008).
Goh, L. Y. & Goh, K. L. Obesity: an epidemiological perspective from Asia and its relationship to gastrointestinal and liver cancers. J. Gastroenterol. Hepatol. 28, Suppl 4, 54–58, (2013).
Petrick, J. L., Kelly, S. P., Altekruse, S. F., McGlynn, K. A. & Rosenberg, P. S. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J. Clin. Oncol. 34, 1787–1794 (2016).
Kjesbu, I. E. et al. Feasibility and diagnostic accuracy of point-of-care abdominal sonography by pocket-sized imaging devices, performed by medical residents. J. Ultrasound Med. 36, 1195–1202 (2017).
Waheed, Y. Transition from millennium development goals to sustainable development goals and hepatitis. Pathog. Glob. Health 109, 353 (2015).
Kenya Outreach Mission. IHPBA http://www.ihpba.org/includes/moxiemanager/data/files/IHPBA%20Outreach%20Kenya%202017%20Leaflet%20WEBSITE.pdf. (2017).
The authors are supported by grant numbers T32 DK07198 from the National Institute of Diabetes and Digestive and Kidney Diseases (J.D.Y.), CA165076, CA186566, CA 221205 and CA 210964 from the National Cancer Institute (L.R.R.) and the French National Research Agency ‘Investissements d’avenir’ program (ANR-15-IDEX-02) (P.H.). The contents of this Review are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Years of life lost
An estimate of the average years a person would have lived if he or she had not died prematurely.
- Age-standardized incidence rate
(ASIR). The incidence rate after accounting for the differences in the age structure of the populations.
- Sociodemographic index
A summary measure of geographical sociodemographic development, determined based on average income per person, educational attainment and total fertility rate.
- Surveillance, Epidemiology, and End Results (SEER)
A National Cancer Institute programme that provides information on the incidence of cancer and survival from cancer in the USA.
- Adjusted odds ratio (AOR)
The ratio of the odds of the presence of an antecedent in those with a positive outcome to the odds in those with a negative outcome after adjusting for other factors that can affect the outcome.
- Population-attributable fraction
The proportion of incidents in the population that are attributable to the risk factor.
- Relative risk
The ratio of the probability of an outcome in an exposed group to the probability of an outcome in an unexposed group.
- Absolute risk
The risk of developing the outcome of interest.
- Direct-acting antiviral (DAA)
A new class of medication that acts directly to target specific steps in the HCV life-cycle.
- Sustained virologic response (SVR)
An undetectable viral titre at least 12 weeks after completing treatment.
- Primary prevention
Preventive interventions that are applied before there is any evidence of disease or injury.
- Hepatitis B immunoglobulin
A human immunoglobulin that is used to prevent the transmission of HBV infection.
An adsorbent for binding toxic substances in the gastrointestinal tract.
- Secondary prevention
Preventive interventions that try to detect a disease early and prevent it from getting worse.
- Child–Pugh score
A classification system for the severity of cirrhosis.
- Up-to-seven criterion
The sum of the largest tumour size in centimetres and the number of tumours ≤7.
- Eastern Cooperative Oncology Group performance status
A performance status score used to assess the ability of a patient to tolerate cancer treatment.
A scoring system for assessing the severity of chronic liver disease which is now used by the United Network for Organ Sharing and Eurotransplant for prioritizing allocation of liver transplants.
A treatment that blocks blood vessels to prevent blood flow to the tumour.
- Heat sink effect
The cooling effect of blood flow leading to incomplete thermal ablation of liver tumours near large blood vessels.
- Bridge therapy
Hepatocellular carcinoma treatment during the waiting time prior to transplantation to prevent tumour progression.
- Lobar ablation
Delivery of high-dose radiation to one lobe of the liver, causing hypotrophy of the treated lobe of the liver.
A form of radiotherapy where a sealed radiation source is placed inside or next to the area requiring treatment.
- Stereotactic body radiation therapy
A focused radiation treatment using several beams of various intensities aimed at different angles to precisely target the tumour.
- Objective response rate
The proportion of patients with a reduction in tumour burden of a predefined amount.
- Immune checkpoint inhibitors
A form of immunotherapy that works by releasing a natural brake on the immune system so that T cells can recognize and attack tumours.
- Sustainable Development Goals
A collection of 17 global goals set by the United Nations General Assembly in 2015 for the year 2030 to end poverty, protect the planet and ensure that all people enjoy peace and prosperity.
About this article
Cite this article
Yang, J.D., Hainaut, P., Gores, G.J. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16, 589–604 (2019). https://doi.org/10.1038/s41575-019-0186-y
This article is cited by
Molecular Biomedicine (2022)
lncRNA MALAT1 promotes HCC metastasis through the peripheral vascular infiltration via miRNA-613: a primary study using contrast ultrasound
World Journal of Surgical Oncology (2022)
ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis
Stem Cell Research & Therapy (2022)
Establishment and validation of a novel prognostic model for non-virus-related hepatocellular carcinoma
Cancer Cell International (2022)
Journal of Nanobiotechnology (2022)